Michael Mingueneau
Vice President, Immunology Sail Biomedicines
Michael Mingueneau is the Vice President of Immunology at SAIL, where he is responsible for establishing a comprehensive understanding of the immunological properties of SAIL’s eRNA platform and building the company’s immunology unit and pipeline. An immunologist and drug discovery leader experienced in peripheral autoimmunity, neuroinflammation, and immuno-oncology, Michael joined SAIL from Biogen, where he spent ten years in roles of increasing responsibility and led programs from early discovery to Phase 1. He completed postdoctoral training at Harvard Medical School following a PhD in Immunology in France.
Seminars
Tuesday 15th September 2026
Disrupting the Autoimmune Disease Treatment Paradigm – Transient, Potent, & Scalable eRNA-based In Vivo CD19 CAR-T Therapy
9:00 am
- Leveraging circular eRNA therapeutics and t-LNPs to drive potent, transient in vivo CAR-T cell engineering
- Revolutionizing the autoimmune treatment paradigm by achieving deep B-cell depletion and “immune reboot” with a non-integrative product
- Replacing ex vivo manufacturing with scalable, off-the-shelf IV-dosed therapy, eliminating the need for lymphoablation
